Toddlers as young as 18 months are being sedated with ketamine and then injected with millions of umbilical cord-derived stem cells – at a cost of up to $20,000 per session – at clinics across the United States. The procedure has no FDA approval for autism. The person who oversees the nation’s health regulatory apparatus has publicly said it’s a good idea.
Despite lacking approval from the U.S. Food and Drug Administration, these stem cell autism treatments continue to gain popularity, largely due to endorsements from high-profile figures such as U.S. Health and Human Services Secretary Robert F. Kennedy Jr. For desperate parents searching for answers, that endorsement carries enormous weight. For child health advocates and regulatory scientists, it’s a warning sign on a scale rarely seen in modern American medicine.
For years, the FDA provided an informational webpage for parents warning them of the dangers of bogus autism treatments, some promoted by anti-vaccine activists and wellness companies. That advisory is now gone. The Department of Health and Human Services told ProPublica it had “retired the webpage during a routine clean up of dated content at the end of 2025.” No replacement resource for parents has been provided.
What’s Actually Being Done to These Children
Across the United States, families of children diagnosed with autism are paying up to $20,000 per session for unapproved stem cell treatments that claim to improve symptoms – often involving intravenous infusions of stem cells derived from umbilical cords, at clinics in states like Florida and Texas.
The treatment process typically requires sedating young children, some as young as 18 months, with ketamine before administering millions of stem cells intravenously. Ketamine is a powerful dissociative anesthetic. Using it on a toddler outside a hospital setting, for a procedure with no regulatory standing, is not a minor procedural detail – it’s a significant medical intervention in its own right.
Clinics market these infusions as “regenerative medicine” that can enhance communication skills, reduce aggressive behaviors, or lessen self-harm in autistic children. The language is carefully chosen. “Regenerative medicine” sounds scientific and forward-looking. It doesn’t tell parents that no large-scale clinical trial has ever confirmed these benefits in children with autism.
The decision to remove the FDA warning page has outraged autism advocates, who argue that there was nothing inaccurate about the information posted on the page, regardless of the last time it was updated. Zoe Gross, a director at the Autistic Self Advocacy Network, told ProPublica: “It may be an older page, but those warnings are still necessary. People are still being preyed on by these alternative treatments like chelation and chlorine dioxide. Those can both kill people.”
The Science That Stem Cell Clinics Don’t Mention
There is no shortage of stem cell research. The problem is what that research actually shows.
A major clinical trial at Duke University randomly assigned 180 autistic children aged 2 to 7 to receive either a cord blood infusion or a placebo. The results, published in the Journal of Pediatrics, showed no evidence that cord blood was associated with improvements in social communication, autism symptoms, or vocabulary across the full study sample. Duke’s research program is one of the most rigorous ever conducted in this space, which makes its findings especially telling. More recently, Duke’s partnership with Cryo-Cell International, a company that banks cord cells and licensed Duke’s intellectual property to pursue autism infusion clinics, has collapsed – a signal that even commercial interest in the science has waned.
For several years, parents of autistic children paid between $10,000 and $15,000 to have their children undergo unproven stem cell and cord blood treatments at Duke through what’s called an expanded access program. That practice drew criticism from ethicists in the stem cell field, who questioned why Duke was charging money for a service when its own clinical trials had not been encouraging. Duke has since quietly discontinued that program.
A broader look at the evidence base confirms the picture. A 2022 meta-analysis published in PMC/NIH found there is insufficient evidence regarding the efficacy and safety of stem cell therapy for autism. A separate 2022 systematic review published in Frontiers in Pediatrics found that evidence across existing studies was compromised by small sample sizes and a lack of standardized injection routes and doses – meaning researchers weren’t even using consistent enough methods to draw meaningful comparisons.
Commercial clinics, by contrast, build their marketing largely on anecdotal reports and testimonials rather than controlled trial data. The FDA’s now-deleted webpage had warned that some products claiming to “cure” or “treat” autism carry “significant health risks.”
Those risks are specific and serious. According to a Fortune investigation, improper injections can lead to clots, infections, blindness, and tumor formation. These are not theoretical concerns – they have been documented in patients who received unapproved stem cell treatments at commercial clinics. For a parent who brought a child in hoping for better eye contact and fewer meltdowns, a tumor or blood clot is not an acceptable trade-off.
The FDA has previously issued warning letters to clinics marketing unapproved stem cell treatments for autism and related conditions, and federal regulators had identified specific operations as functioning outside the law. Some providers have even moved operations abroad, such as to Tijuana, Mexico, where regulatory standards are less strict.
RFK Jr.’s Role – and His Personal History With Stem Cells
Robert F. Kennedy Jr., who oversees the nation’s biomedical research and medical regulatory apparatus, said he had what he described as a stem cell treatment in Antigua that helped him “enormously.” Kennedy has spasmodic dysphonia, a neurological condition that causes involuntary spasms of the vocal cords and accounts for his distinctive raspy voice. He did not identify the physician who treated him, the type of stem cell treatment used, or the clinic involved, but he said, “Why did I have to go to Antigua for that?” – suggesting the U.S. would soon ease its regulation of clinics that promise unproven stem cell treatments.
That comment was not incidental. In May 2025, HHS Secretary Kennedy expressed interest in expanding access to experimental therapies, including stem cells, at a time when one of the largest trials in the field had already missed its endpoints and Duke’s research partnership had collapsed.
Kennedy’s broader stance on autism is consistent with this pattern. Many autism researchers and advocates have been wary of Kennedy due to his long-held stance that vaccines cause autism. Peer-reviewed studies conducted worldwide, published over decades in leading scientific journals, have rejected such a link. During his confirmation hearings, Kennedy refused to say that vaccines do not cause autism – despite a large body of evidence showing there is no link.
Paul Offit, MD, director of the Vaccine Education Center at Children’s Hospital of Philadelphia and a professor of pediatrics at the University of Pennsylvania, told ProPublica that Kennedy’s removal of committee members with solid expertise in favor of people who support alternative medicine shows that the secretary is “perfectly willing to embrace bogus therapies.”
Kennedy, during his tenure as health secretary under the Trump administration, has supported expanding access to experimental stem cell therapies for autism and other conditions, and has been linked to summits promoting such treatments and has appointed advocates of alternative therapies to federal autism committees.
For parents of autistic children, navigating this environment is genuinely difficult. When the country’s top health official is publicly endorsing treatments the FDA has never approved, and the FDA’s own warnings page has been deleted, the safeguard architecture that families have historically relied upon has been quietly dismantled.
What Parents Are Actually Paying For
Families of children diagnosed with autism are paying up to $20,000 per session for procedures that have not cleared the FDA’s approval process. That’s not a price for a proven treatment – it’s a price for participation in an unregulated experiment, with the child as the subject and the parents absorbing all the financial and physical risk.
There is no standardized protocol. Different clinics use different stem cell sources, different doses, different delivery methods, and different sedation approaches. The Department of Health and Human Services told the BMJ that the now-deleted FDA warning page was “retired during a routine clean up” of dated content, with the spokesperson noting that other older articles were also removed. What that framing omits is that no replacement resource for parents has been provided.
Paul Knoepfler, PhD, a stem cell researcher and professor at UC Davis School of Medicine who has followed this field for over a decade, noted in a detailed analysis that the Duke Phase II trial showed no significant efficacy of cord blood for autism – and characterized the results as what he called “a probable stop sign” for the field. A similar earlier trial of cord cells for autism by Sutter Health also missed its endpoint, and beyond cord cells, no encouraging data from trials of stem cells for autism more generally has emerged.
Read More: RFK Jr. and the Global Vaccine Fight
What to Do Now
Parents of autistic children deserve both honest information and genuine support. The absence of an FDA-approved stem cell autism treatment isn’t a regulatory conspiracy – it reflects the fact that the evidence bar for proving something safe and effective in children has not been cleared. The FDA cautions parents against seeking these treatments outside approved clinical trials, warning that many clinics operate illegally and may exploit vulnerable families.
If a clinic is offering a stem cell infusion for autism and charging $10,000 to $20,000 for it, the questions to ask are direct: What phase of clinical trial supports this? Is this procedure registered at ClinicalTrials.gov? Has the FDA reviewed it under an Investigational New Drug application? If the clinic can’t answer all three in writing, that’s a clear signal.
Evidence-based therapies for autism do exist and have decades of data behind them. The UNC TEACCH Autism Program – developed at the University of North Carolina and now operating across seven outpatient clinics – uses structured teaching methods grounded in the understanding that autistic children benefit from visual supports and consistent, predictable environments. A 2011 review of more than 150 autism-intervention studies found that TEACCH had the strongest evidence of educational benefits of any recognized program. Behavioral and speech-language interventions are recommended by the CDC and have the randomized controlled trial evidence that stem cell clinics simply cannot produce.
Spending $20,000 on an unproven infusion means $20,000 not spent on speech therapy, behavioral support, or structured educational programs with actual evidence behind them. For families weighing their options, that trade-off is worth keeping at the center of the conversation.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Could Posture or Pelvic Tilt Signal ADHD or Autism Traits?